{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:43:55Z","timestamp":1749728635844},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00059-021-05068-5","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T21:45:01Z","timestamp":1633470301000},"page":"19-30","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ESC\/EACTS-Leitlinien 2021 zum Management von Herzklappenerkrankungen"],"prefix":"10.1007","volume":"47","author":[{"given":"F. S.","family":"Nettersheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"5068_CR1","volume-title":"Deutscher Herzbericht 2020","author":"Deutsche Herzstiftung e.\u202fV.","year":"2021","unstructured":"Deutsche Herzstiftung e.\u202fV. (2021) Deutscher Herzbericht 2020. Thieme, Frankfurt am Main"},{"key":"5068_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00570-z","author":"S Coffey","year":"2021","unstructured":"Coffey\u00a0S, Roberts-Thomson\u00a0R, Brown\u00a0A et al (2021) Global epidemiology of valvular heart disease. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-021-00570-z","journal-title":"Nat Rev Cardiol"},{"key":"5068_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/EURHEARTJ\/EHY668","volume":"40","author":"BD Prendergast","year":"2019","unstructured":"Prendergast\u00a0BD, Baumgartner\u00a0H, Delgado\u00a0V et\u00a0al (2019) Transcatheter heart valve interventions: where are we? Where are we going? Eur Heart\u00a0J 40:422\u2013440. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHY668","journal-title":"Eur Heart J"},{"key":"5068_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner\u00a0H, Falk\u00a0V, Bax\u00a0JJ et\u00a0al (2017) 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart\u00a0J 38:2739\u20132791. https:\/\/doi.org\/10.1093\/eurheartj\/ehx391","journal-title":"Eur Heart J"},{"key":"5068_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAB395","author":"A Vahanian","year":"2021","unstructured":"Vahanian\u00a0A, Beyersdorf\u00a0F, Praz\u00a0F et al (2021) 2021 ESC\/EACTS guidelines for the management of valvular heart diseasedeveloped by the task force for the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS). Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB395","journal-title":"Eur Heart J"},{"key":"5068_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/NRCARDIO.2010.202","volume":"8","author":"B Iung","year":"2011","unstructured":"Iung\u00a0B, Vahanian\u00a0A (2011) Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8:162\u2013172. https:\/\/doi.org\/10.1038\/NRCARDIO.2010.202","journal-title":"Nat Rev Cardiol"},{"key":"5068_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/9.suppl_E.57","volume":"9","author":"D Horstkotte","year":"1988","unstructured":"Horstkotte\u00a0D, Loogen\u00a0F (1988) The natural history of aortic valve stenosis. Eur Heart\u00a0J 9:57\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/9.suppl_E.57","journal-title":"Eur Heart J"},{"key":"5068_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2018.3152","volume":"3","author":"P Lancellotti","year":"2018","unstructured":"Lancellotti\u00a0P, Magne\u00a0J, Dulgheru\u00a0R et\u00a0al (2018) Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA Cardiol 3:1060\u20131068. https:\/\/doi.org\/10.1001\/jamacardio.2018.3152","journal-title":"JAMA Cardiol"},{"key":"5068_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jcmg.2018.07.029","volume":"12","author":"Y Bohbot","year":"2019","unstructured":"Bohbot\u00a0Y, de Meester de Ravenstein\u00a0C, Chadha\u00a0G et\u00a0al (2019) Relationship between left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis. JACC Cardiovasc Imaging 12:38\u201348. https:\/\/doi.org\/10.1016\/j.jcmg.2018.07.029","journal-title":"JACC Cardiovasc Imaging"},{"key":"5068_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1912846","volume":"382","author":"D-H Kang","year":"2020","unstructured":"Kang\u00a0D\u2011H, Park\u00a0S\u2011J, Lee\u00a0S\u2011A et al (2020) Early surgery or conservative care for asymptomatic aortic stenosis. N\u00a0Engl J Med 382:111\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1912846","journal-title":"N Engl J Med"},{"key":"5068_CR11","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1161\/01.CIR.0000047200.36165.B8","volume":"106","author":"A Cribier","year":"2002","unstructured":"Cribier\u00a0A, Eltchaninoff\u00a0H, Bash\u00a0A et\u00a0al (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106:3006\u20133008. https:\/\/doi.org\/10.1161\/01.CIR.0000047200.36165.B8","journal-title":"Circulation"},{"key":"5068_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","volume":"363","author":"MB Leon","year":"2010","unstructured":"Leon\u00a0MB, Smith\u00a0CR, Mack\u00a0M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N\u00a0Engl J Med 363:1597\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1008232","journal-title":"N Engl J Med"},{"key":"5068_CR13","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith\u00a0CR, Leon\u00a0MB, Mack\u00a0MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N\u00a0Engl J Med 364:2187\u20132198. https:\/\/doi.org\/10.1056\/NEJMoa1103510","journal-title":"N Engl J Med"},{"key":"5068_CR14","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","volume":"370","author":"DH Adams","year":"2014","unstructured":"Adams\u00a0DH, Popma\u00a0JJ, Reardon\u00a0MJ et al (2014) Transcatheter aortic-valve replacement with a\u00a0self-expanding prosthesis. N\u00a0Engl J Med 370:1790\u20131798. https:\/\/doi.org\/10.1056\/NEJMoa1400590","journal-title":"N Engl J Med"},{"key":"5068_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon\u00a0MB, Smith\u00a0CR, Mack\u00a0MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N\u00a0Engl J Med 374:1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1514616","journal-title":"N Engl J Med"},{"key":"5068_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","volume":"376","author":"MJ Reardon","year":"2017","unstructured":"Reardon\u00a0MJ, Van Mieghem\u00a0NM, Popma\u00a0JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N\u00a0Engl J Med 376:1321\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1700456","journal-title":"N Engl J Med"},{"key":"5068_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack\u00a0MJ, Leon\u00a0MB, Thourani\u00a0VH et al (2019) Transcatheter aortic-valve replacement with a\u00a0balloon-expandable valve in low-risk patients. N\u00a0Engl J Med 380:1695\u20131705. https:\/\/doi.org\/10.1056\/NEJMoa1814052","journal-title":"N Engl J Med"},{"key":"5068_CR18","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma\u00a0JJ, Deeb\u00a0GM, Yakubov\u00a0SJ et al (2019) Transcatheter aortic-valve replacement with a\u00a0self-expanding valve in low-risk patients. N\u00a0Engl J Med 380:1706\u20131715. https:\/\/doi.org\/10.1056\/NEJMoa1816885","journal-title":"N Engl J Med"},{"key":"5068_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jacc.2020.12.052","volume":"77","author":"MB Leon","year":"2021","unstructured":"Leon\u00a0MB, Mack\u00a0MJ, Hahn\u00a0RT et\u00a0al (2021) Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J\u00a0Am Coll Cardiol 77:1149\u20131161. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.052","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR20","first-page":"E72","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto\u00a0CM, Nishimura\u00a0RA, Bonow\u00a0RO et\u00a0al (2021) 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 143:E72\u2013E227","journal-title":"Circulation"},{"key":"5068_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo\u00a0VT, Gardin\u00a0JM, Skelton\u00a0TN et al (2006) Burden of valvular heart diseases: a\u00a0population-based study. Lancet 368:1005\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(06)69208-8","journal-title":"Lancet"},{"key":"5068_CR22","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/J.JCMG.2018.11.022","volume":"12","author":"C de Meester","year":"2019","unstructured":"de Meester\u00a0C, Gerber\u00a0BL, Vancraeynest\u00a0D et al (2019) Do guideline-based indications result in an outcome penalty for patients with severe aortic regurgitation? JACC Cardiovasc Imaging 12:2126\u20132138. https:\/\/doi.org\/10.1016\/J.JCMG.2018.11.022","journal-title":"JACC Cardiovasc Imaging"},{"key":"5068_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/J.JACC.2019.01.024","volume":"73","author":"LT Yang","year":"2019","unstructured":"Yang\u00a0LT, Michelena\u00a0HI, Scott\u00a0CG et\u00a0al (2019) Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines. J\u00a0Am Coll Cardiol 73:1741\u20131752. https:\/\/doi.org\/10.1016\/J.JACC.2019.01.024","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR24","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/J.JACC.2016.08.045","volume":"68","author":"A Mentias","year":"2016","unstructured":"Mentias\u00a0A, Feng\u00a0K, Alashi\u00a0A et al (2016) Long-term outcomes in patients with\u00a0aortic regurgitation and preserved\u00a0left ventricular ejection fraction. J\u00a0Am Coll Cardiol 68:2144\u20132153. https:\/\/doi.org\/10.1016\/J.JACC.2016.08.045","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR25","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/eurheartj\/ehz314","volume":"40","author":"V Dziadzko","year":"2019","unstructured":"Dziadzko\u00a0V, Dziadzko\u00a0M, Medina-Inojosa\u00a0JR et al (2019) Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur Heart\u00a0J 40:2194\u20132202. https:\/\/doi.org\/10.1093\/eurheartj\/ehz314","journal-title":"Eur Heart J"},{"key":"5068_CR26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/eurheartj\/ehx465","volume":"39","author":"F Grigioni","year":"2018","unstructured":"Grigioni\u00a0F, Clavel\u00a0M\u2011A, Vanoverschelde\u00a0J\u2011L et al (2018) The MIDA mortality risk score: development and external validation of a\u00a0prognostic model for early and late death in degenerative mitral regurgitation. Eur Heart\u00a0J 39:1281\u20131291. https:\/\/doi.org\/10.1093\/eurheartj\/ehx465","journal-title":"Eur Heart J"},{"key":"5068_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contributio. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"5068_CR28","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2007.08.019","volume":"50","author":"C Ypenburg","year":"2007","unstructured":"Ypenburg\u00a0C, Lancellotti\u00a0P, Tops\u00a0LF et\u00a0al (2007) Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J\u00a0Am Coll Cardiol 50:2071\u20132077. https:\/\/doi.org\/10.1016\/j.jacc.2007.08.019","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR29","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jcmg.2018.06.013","volume":"12","author":"PE Bartko","year":"2019","unstructured":"Bartko\u00a0PE, Arfsten\u00a0H, Heitzinger\u00a0G et al (2019) Papillary muscle dyssynchrony-mediated functional mitral regurgitation: mechanistic insights and modulation by cardiac resynchronization. JACC Cardiovasc Imaging 12:1728\u20131737. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.013","journal-title":"JACC Cardiovasc Imaging"},{"key":"5068_CR30","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"J-F Obadia","year":"2018","unstructured":"Obadia\u00a0J\u2011F, Messika-Zeitoun\u00a0D, Leurent\u00a0G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N\u00a0Engl J Med 379:2297\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1805374","journal-title":"N Engl J Med"},{"key":"5068_CR31","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ejhf.1616","volume":"21","author":"B Iung","year":"2019","unstructured":"Iung\u00a0B, Armoiry\u00a0X, Vahanian\u00a0A et\u00a0al (2019) Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2\u00a0years. Eur J Heart Fail 21:1619\u20131627. https:\/\/doi.org\/10.1002\/ejhf.1616","journal-title":"Eur J Heart Fail"},{"key":"5068_CR32","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone\u00a0GW, Lindenfeld\u00a0J, Abraham\u00a0WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med 379:2307\u20132318. https:\/\/doi.org\/10.1056\/NEJMoa1806640","journal-title":"N Engl J Med"},{"key":"5068_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2020.12.047","volume":"77","author":"MJ Mack","year":"2021","unstructured":"Mack\u00a0MJ, Lindenfeld\u00a0JA, Abraham\u00a0WT et al (2021) 3\u2011year outcomes of transcatheter mitral valve repair in patients with heart failure. J\u00a0Am Coll Cardiol 77:1029\u20131040. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.047","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","volume":"12","author":"PA Grayburn","year":"2019","unstructured":"Grayburn\u00a0PA, Sannino\u00a0A, Packer\u00a0M (2019) Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 12:353\u2013362","journal-title":"JACC Cardiovasc Imaging"},{"key":"5068_CR35","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/nejmoa1602003","volume":"374","author":"RE Michler","year":"2016","unstructured":"Michler\u00a0RE, Smith\u00a0PK, Parides\u00a0MK et al (2016) Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N\u00a0Engl J Med 374:1932\u20131941. https:\/\/doi.org\/10.1056\/nejmoa1602003","journal-title":"N Engl J Med"},{"key":"5068_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcmg.2018.06.014","volume":"12","author":"Y Topilsky","year":"2019","unstructured":"Topilsky\u00a0Y, Maltais\u00a0S, Medina Inojosa\u00a0J et\u00a0al (2019) Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 12:433\u2013442. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.014","journal-title":"JACC Cardiovasc Imaging"},{"key":"5068_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","volume":"30","author":"WA Zoghbi","year":"2017","unstructured":"Zoghbi\u00a0WA, Adams\u00a0D, Bonow\u00a0RO et\u00a0al (2017) Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J\u00a0Am Soc Echocardiogr 30:303\u2013371. https:\/\/doi.org\/10.1016\/j.echo.2017.01.007","journal-title":"J Am Soc Echocardiogr"},{"key":"5068_CR38","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ehjci\/jex139","volume":"18","author":"RT Hahn","year":"2017","unstructured":"Hahn\u00a0RT, Zamorano\u00a0JL (2017) The need for a\u00a0new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging 18:1342\u20131343. https:\/\/doi.org\/10.1093\/ehjci\/jex139","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"5068_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.ATHORACSUR.2019.03.004","volume":"108","author":"M Hamandi","year":"2019","unstructured":"Hamandi\u00a0M, Smith\u00a0RL, Ryan\u00a0WH et\u00a0al (2019) Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg 108:11\u201315. https:\/\/doi.org\/10.1016\/J.ATHORACSUR.2019.03.004","journal-title":"Ann Thorac Surg"},{"key":"5068_CR40","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/HEARTJNL-2019-315004","volume":"105","author":"AN Kadri","year":"2019","unstructured":"Kadri\u00a0AN, Menon\u00a0V, Sammour\u00a0YM et\u00a0al (2019) Outcomes of patients with severe tricuspid regurgitation and congestive heart failure. Heart 105:1813\u20131817. https:\/\/doi.org\/10.1136\/HEARTJNL-2019-315004","journal-title":"Heart"},{"key":"5068_CR41","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0140-6736(19)32600-5","volume":"394","author":"G Nickenig","year":"2019","unstructured":"Nickenig\u00a0G, Weber\u00a0M, Lurz\u00a0P et al (2019) Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6\u2011month outcomes of the TRILUMINATE single-arm study. Lancet 394:2002\u20132011. https:\/\/doi.org\/10.1016\/S0140-6736(19)32600-5","journal-title":"Lancet"},{"key":"5068_CR42","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jacc.2019.01.062","volume":"73","author":"G Nickenig","year":"2019","unstructured":"Nickenig\u00a0G, Weber\u00a0M, Schueler\u00a0R et al (2019) 6\u2011month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J\u00a0Am Coll Cardiol 73:1905\u20131915. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.062","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR43","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.jcin.2020.07.008","volume":"13","author":"RT Hahn","year":"2020","unstructured":"Hahn\u00a0RT, Kodali\u00a0S, Fam\u00a0N et\u00a0al (2020) Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC Cardiovasc Interv 13:2482\u20132493. https:\/\/doi.org\/10.1016\/j.jcin.2020.07.008","journal-title":"JACC Cardiovasc Interv"},{"key":"5068_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/J.JCIN.2020.11.045","volume":"14","author":"N Fam","year":"2021","unstructured":"Fam\u00a0N, von Bardeleben\u00a0RS, Hensey\u00a0M et al (2021) Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv 14:501\u2013511. https:\/\/doi.org\/10.1016\/J.JCIN.2020.11.045","journal-title":"JACC Cardiovasc Interv"},{"key":"5068_CR45","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/J.JCIN.2020.03.026","volume":"13","author":"FL Lu","year":"2020","unstructured":"Lu\u00a0FL, Ma\u00a0Y, An\u00a0Z et al (2020) First-in-man experience of transcatheter tricuspid valve replacement with LuX-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv 13:1614\u20131616. https:\/\/doi.org\/10.1016\/J.JCIN.2020.03.026","journal-title":"JACC Cardiovasc Interv"},{"key":"5068_CR46","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/J.JACC.2019.09.028","volume":"74","author":"M Taramasso","year":"2019","unstructured":"Taramasso\u00a0M, Benfari\u00a0G, van der Bijl\u00a0P et\u00a0al (2019) Transcatheter versus medical treatment of patients with symptomatic severe\u00a0tricuspid regurgitation. J\u00a0Am Coll Cardiol 74:2998\u20133008. https:\/\/doi.org\/10.1016\/J.JACC.2019.09.028","journal-title":"J Am Coll Cardiol"},{"key":"5068_CR47","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/EURHEARTJ\/EHW210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof\u00a0P, Benussi\u00a0S, Kotecha\u00a0D et\u00a0al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J 37:2893\u20132962. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHW210","journal-title":"Eur Heart J"},{"key":"5068_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/EURHEARTJ\/EHAA612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks\u00a0G, Potpara\u00a0T, Dagres\u00a0N et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS) the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart\u00a0J 42:373\u2013498. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAA612","journal-title":"Eur Heart J"},{"key":"5068_CR49","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/J.AMJCARD.2018.04.006","volume":"122","author":"F Maes","year":"2018","unstructured":"Maes\u00a0F, Stabile\u00a0E, Ussia\u00a0GP et al (2018) Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol 122:310\u2013315. https:\/\/doi.org\/10.1016\/J.AMJCARD.2018.04.006","journal-title":"Am J Cardiol"},{"key":"5068_CR50","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJMOA2017815","volume":"383","author":"J Brouwer","year":"2020","unstructured":"Brouwer\u00a0J, Nijenhuis\u00a0VJ, Delewi\u00a0R et al (2020) Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N\u00a0Engl J Med 383:1447\u20131457. https:\/\/doi.org\/10.1056\/NEJMOA2017815","journal-title":"N Engl J Med"},{"key":"5068_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas\u00a0GD, Tijssen\u00a0JGP, W\u00f6hrle\u00a0J et al (2020) A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N\u00a0Engl J Med 382:120\u2013129. https:\/\/doi.org\/10.1056\/NEJMoa1911425","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05068-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T08:03:06Z","timestamp":1644912186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05068-5"}},"subtitle":["Was sind die wichtigsten Neuerungen?"],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5068"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05068-5","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"9 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0S.\u00a0Nettersheim gibt an, dass kein Interessenkonflikt besteht. S.\u00a0Baldus erhielt Forschungsunterst\u00fctzung und Vortragshonorare von Abbott, Edwards Lifescience und Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}